S. Pianko

发表

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.

E. Barnes, J. George, G. Foster, 2015, Gastroenterology.

Randomized trial of albinterferon alfa‐2b every 4 weeks for chronic hepatitis C virus genotype 2/3

P. Komolmit, S. Zeuzem, G. Feutren, 2012, Journal of viral hepatitis.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

D. Nelson, M. Rodríguez-Torres, E. Pulkstenis, 2010, Gastroenterology.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

E. Schiff, G. Everson, K. Kowdley, 2013, The New England journal of medicine.

Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease

M. Bailey, S. Roberts, S. Pianko, 2005, Journal of gastroenterology and hepatology.

Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C

K. Kaita, S. Zeuzem, E. Pulkstenis, 2008, Hepatology.

A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection

J. McHutchison, K. Patel, W. Reynolds, 2002, Genes and Immunity.

Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.

B. Bacon, Z. Goodman, E. Brunt, 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

The Clinical Utility of Using Catrimox-14-Treated Whole Blood in Detecting Hepatitis C Virus RNA

J. McHutchison, K. Patel, P. Pockros, 2005, Antiviral therapy.

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis

T. Asselah, A. Mangia, S. Zeuzem, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study

G. Dore, P. Gow, S. Bollipo, 2017, Antiviral therapy.

HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C

J. Koziol, B. Portmann, L. Lebeck, 2006, Hepatology.

Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting

S. Roberts, S. Pianko, S. Nguyen, 2006, Journal of viral hepatitis.

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

P. Angus, G. Dore, S. Pol, 2016, Hepatology.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

T. Berg, T. Asselah, A. Mangia, 2015, The New England journal of medicine.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, V. de Lédinghen, E. Schiff, 2017, The New England journal of medicine.

Hepatology Clinical

D. Liew, F. Amico, A. Gorelik, 2017 .

Treatment of hepatitis C with interferon and ribavirin

J. McHutchison, S. Pianko, 2000, Journal of gastroenterology and hepatology.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Manfred von der Ohe, A. Coates, C. Trautwein, 2019, The Lancet.

Risks of a range of alcohol intake on hepatitis C‐related fibrosis

T. Wright, A. Bostrom, J. McHutchison, 2004, Hepatology.

Efficacy and tolerability of pegylated interferon‐α‐2a in chronic hepatitis B: A multicenter clinical experience

V. Sundararajan, S. Bell, W. Cheng, 2012, Journal of gastroenterology and hepatology.

Inflammatory Bowel Disease Clinical

M. Appleyard, P. Bampton, G. Radford-Smith, 2016, Journal of gastroenterology and hepatology.

Rituximab-induced Crohn’s disease

H. Prince, S. Pianko, P. Varma, 2017, Scandinavian journal of gastroenterology.

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C

J. McHutchison, K. Patel, T. Poynard, 2003, Journal of viral hepatitis.

Short‐term intraperitoneal catheters: An ambulatory care intervention for refractory ascites secondary to cirrhosis during COVID‐19

S. Bell, S. Pianko, Suong T T Le, 2021, JGH open : an open access journal of gastroenterology and hepatology.

Sucralfate as an Alternative to Bismuth in Quadruple Therapy for Helicobacter pylori Eradication

T. Bolin, S. Pianko, M. Korman, 1997, Helicobacter.

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon‐α

R. Hammond, S. Bell, P. Desmond, 2013, Journal of gastroenterology and hepatology.

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.

I. Yang, J. Ware, M. Neary, 2001, Journal of hepatology.

The use of topical calcineurin inhibitors for pyoderma gangrenosum in inflammatory bowel disease: A case series

P. De Cruz, M. Sparrow, S. Pianko, 2020 .

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

Stefan Zeuzem, Steven Knox, A. Mangia, 2017, Journal of hepatology.

The Direct Cost of Managing Patients With Chronic Hepatitis B Infection in Australia

P. Gow, S. Strasser, S. Roberts, 2004, Journal of clinical gastroenterology.

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

R. Yu, F. A. Dorr, J. McHutchison, 2006, Journal of hepatology.

Chronic hepatitis B: new therapies on the horizon?

J. McHutchison, S. Pianko, 1999, The Lancet.

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection

C. Stedman, K. Reddy, G. Dore, 2015, Annals of Internal Medicine.

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

A. Neumann, S. Zeuzem, E. Pulkstenis, 2009, Journal of hepatology.

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

S. Sarin, P. Komolmit, K. Brown, 2013, Journal of viral hepatitis.

Hepatic iron overload does not prevent a sustained virological response to interferon-α therapy: a long term follow-up study in hepatitis C-infected patients with β thalassemia major

D. Bowden, S. Bowden, S. Pianko, 2002, American Journal of Gastroenterology.

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Chih-Wei Lin, Joel Gallant, M. Buti, 2018, Hepatology.

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

M. Buti, J. Gallant, T. Pilot‐Matias, 2017 .

Fas‐mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection

G. Ostapowicz, P. Desmond, S. Pianko, 2001, Journal of viral hepatitis.

Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse

M. Hellard, P. Gow, M. Sinclair, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Immunomodulator use does not prevent first loss of response to anti‐tumour necrosis factor alpha therapy in inflammatory bowel disease: long‐term outcomes in a real‐world cohort

L. Prideaux, M. Swan, S. Pianko, 2019, Internal medicine journal.

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

K. Kowdley, D. Nelson, D. Brainard, 2013 .

Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma.

H. Prince, S. Pianko, P. Bhathal, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection.

J. McHutchison, L. Nyberg, S. Pianko, 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Kinetics of hepatitis C virus reinfection after liver transplantation

John McHutchison, Ruy M Ribeiro, Alan S Perelson, 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks

H. Mo, B. Doehle, D. Brainard, 2015 .

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?

L. Lipton, S. Pianko, V. Knight, 2021, Current oncology.

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.

J. Albrecht, A. Reid, T. Morgan, 2000, Gastroenterology.

MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure

M. Buti, J. Gallant, T. Pilot‐Matias, 2017 .

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

M. Torbenson, S. Zeuzem, D. Nelson, 2011, Gut.

Induction interferon and ribavirin for re‐treatment of chronic hepatitis C patients unresponsive to interferon alone

R. Batey, P. Bhathal, G. Marinos, 2003, Alimentary pharmacology & therapeutics.